Cargando…
Identification of a Novel SLC8A1-ALK Fusion and Non-Canonical Expression Significantly Responding to ALK-TKIs in Lung Adenocarcinoma: A Case Report
BACKGROUND: Approximately 2–7% of patients with non-small cell lung cancer harbor anaplastic lymphoma kinase (ALK) rearrangement events. Of note, typical ALK actionable rearrangements are sensitive to treatment with tyrosine kinase inhibitors (TKIs). However, different types of ALK fusion influence...
Autores principales: | Zhu, Xingyu, He, Yuqi, Wang, Yin, Lei, Yan, Su, Xiaoxing, Liu, Yifan, Wu, Shuangxiu, He, Zhengfu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486277/ https://www.ncbi.nlm.nih.gov/pubmed/34611409 http://dx.doi.org/10.2147/OTT.S319845 |
Ejemplares similares
-
Response to ALK‐TKIs in a lung adenocarcinoma patient harboring dual
DCTN1‐ALK
and
ALK‐CLIP4
rearrangements
por: Gao, Fangfang, et al.
Publicado: (2022) -
A Novel Intergenic Gene Between SLC8A1 and PKDCC-ALK Fusion Responds to ALK TKI WX-0593 in Lung Adenocarcinoma: A Case Report
por: Du, Jia, et al.
Publicado: (2022) -
Classical ALK G1202R resistance mutation was identified in a lung adenocarcinoma patient with rare LOC388942-ALK fusion after sequential treatment with ALK-TKIs and anlotinib: a case report
por: Zhai, Xiaoqian, et al.
Publicado: (2022) -
SMPD3‐ALK: A novel ALK fusion gene in lung adenocarcinoma
por: Liang, Yuepei, et al.
Publicado: (2021) -
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
por: Okada, Koutaroh, et al.
Publicado: (2019)